-
Paving the way to cancer prevention
Wycliffe “Wyc” Grousbeck and Emilia Fazzalari are firm believers that “good things don’t come easy.” As philanthropic and entrepreneurial leaders in the Boston community, they seek out innovative and exceptional people who are tackling groundbreaking endeavors that are simply too compelling to refuse.
-
Damon Runyon invests in promising early career scientists
The Damon Runyon Cancer Research Foundation has awarded more than $3.2 million in grants to nine early career investigators at Dana-Farber, including Mounica Vallurupalli, MD, who was named the foundation’s first Damon Runyon-David M. Livingston, MD, Physician-Scientist.
-
New grants advance key research across multiple disease areas
Longtime Dana-Farber supporter Conquer Cancer,® the ASCO Foundation, recently awarded $1.45 million to support seven researchers pursuing projects in a wide range of disease areas.
-
Schaubert Family endows visionary fellowship for lung cancer research
For nearly a decade, the Schaubert family has been a dedicated supporter of lung cancer research at Dana-Farber.
-
The Gray Foundation empowers team science against BRCA-mutated cancers
Philanthropy has transformative power to address society’s intractable challenges. The Gray Foundation is committed to this goal and, with two grants totaling nearly $6 million, is harnessing this power for good through The Dana-Farber Campaign.
-
Exceptional care inspires planned gift to gynecologic oncology
Despite all she’s been through, Jill Altman considers herself lucky. For nearly half her life, Jill has had run-ins with cancer—starting when she was diagnosed with low-malignant potential ovarian cancer in 1996 at just 22 years old.
-
Young patient inspires new fund at Dana-Farber
In a video recorded in early 2021, a then 12-year-old Orli Wildman Halpern explained to a live New York Times audience over Instagram the experience of living with, and through, treatments for hepatoblastoma, a rare liver cancer primarily seen in toddlers.
-
Furthering research into new treatment for Waldenstrom’s macroglobulinemia
More than 10 years ago, Steven Treon, MD, PhD, and his colleagues were the first scientists to discover that MYD88 mutations, which occur in more than 95% of patients with Waldenström’s macroglobulinemia (WM), rely on the BTK protein to function.
-
Lustgarten grant accelerates therapeutic discovery in pancreatic cancer
The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world, funding preeminent pancreatic cancer researchers, driving the pursuit of bold and innovative science toward earlier detection and better treatments, and transforming pancreatic cancer into a curable disease.
-
Kendall Family prioritizes innovation in pancreatic cancer
In cancer research, hope can be realized in how we innovate. Inventive clinical trials can lead to novel approaches and new, accessible medicines that ultimately bring better outcomes to patients.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.